查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371891

到 2030 年的全球生技藥品市場預測：按產品、類型、用途和地區進行的全球分析

Biologic Therapeutics Market Forecasts to 2030 - Global Analysis By Product (Gene Therapy, Cell Therapy, Vaccines, Antibody Therapeutics and Other Products), Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球生技藥品市場規模為 4,575.6 億美元，預計將以 11.3% 的年複合成長率成長，到 2030 年達到 9,680.8 億美元。

專注於生物來源治療藥物的開發、生產和行銷的製藥工業部門被稱為生技藥品市場。這些複雜的化學物質是利用活生物體或活生物體的一部分製成的，例如蛋白質、抗體、核酸和細胞。又稱生技藥品或生物製藥。

據世界衛生組織 (WHO) 稱，疫苗是減輕全球疾病負擔最有力、最具成本效益的方法之一，預計每年可挽救 200-300 萬人的生命。

與老齡化相關的慢性病的增加和生技藥品管道的擴大

癌症、自體免疫疾病和代謝性疾病等慢性疾病的增加增加了對有效替代療法的需求。生技藥品提供量身定做的、標靶治療，可以解決許多疾病的根本原因，從而推動市場擴張。此外，生技藥品開發還獲得了製藥和生物技術行業的大量資金。重組蛋白、細胞和基因療法以及單株抗體等生技藥品的發展正在重振市場並刺激創新。

開發、生產、製造和供應鏈管理成本高且極為複雜。

開發和製造生技藥品需要複雜的程序和大量的成本，包括研發、臨床試驗和製造設施。這些高成本可能會限制生技藥品的可得性和可負擔性，特別是在資源有限的醫療保健系統中。然而，由於其複雜性，生技藥品需要專門的生產設施和程序。確保一致的品質、可擴展性和維持強大的供應鏈可能很困難，並且會影響生技藥品治療的可及性和可負擔性。

生物技術和基因工程的進步以及有利的法規條件

生物技術、基因工程和重組 DNA 技術的進步正在增加創造創新生物療法的潛力。這些技術的發展使得能夠生產更複雜、更有特異性的生物藥品，擴大了可用治療方法的數量。此外，歐洲藥品管理局（EMA）和美國食品藥物管理局（FDA）等法規機構也為生技藥品的核准制定了精確的規則並​​加快了核准程序。這些管理體制為生技藥品的開發、評估和行銷提供了有利的環境。

高水準的法規以及對免疫抗原性和安全性的擔憂

儘管有有利的法律規範，但生技藥品的核准過程複雜且要求嚴格。公司必須進行廣泛的臨床前和臨床試驗來證明安全性、有效性和品質，這需要很長時間並花費大量資金。然而，可能會誘導患者對生物治療的免疫反應，引發對其安全性和免疫抗原性的擔憂。這些免疫反應會不同程度地影響治療的有效性和安全性。有效監測和管理此類問題對於有效使用生物治療至關重要。

COVID-19 的影響

COVID-19 的爆發使得高效的疫苗生產和分發變得至關重要。因此，利用 mRNA 和病毒載體疫苗等生物平台進行的疫苗研發顯著增加。 COVID-19疫苗的有效研發和應用凸顯了生物治療的前景，並強調了生物技術領域在感染疾病控制中的重要性。

血液製品領域預計在預測期內規模最大

預測期內，血液製品領域佔據最大佔有率。血液衍生產品，包括免疫球蛋白、凝血因子和血漿衍生蛋白，用於治療各種血液疾病和免疫力缺乏，也被認為是生物療法的一部分。這些物品的使用對於治療許多血液疾病、免疫力缺乏和其他疾病至關重要。

預計細胞治療領域在預測期內將經歷最高的年複合成長率。

據估計，細胞治療領域在預測期內將出現良好的成長。活細胞用於細胞療法來治療和治癒疾病。細胞療法是一個快速發展的領域，旨在替換、修復和修復受損或患病的細胞和組織。此外，細胞療法在許多治療領域顯示出潛力，包括腫瘤學、心血管疾病、神經退化性疾病疾病和自體免疫疾病。

比最大的地區

由於生物治療行業經歷了重大發展和創新，並正在成為一個充滿活力和快速變化的中心，預計亞太地區將在預測期內佔據最大佔有率。該地區與許多擁有自己的醫療保健系統的國家相連，使其成為一個複雜但有吸引力的市場。此外，癌症、糖尿病和自體免疫疾病等慢性疾病的流行增加了對生物治療的需求。

複合年複合成長率最高的地區

據估計，亞太地區的年複合成長率最高。不斷成長的中等收入人口和不斷上漲的醫療保健費用正在擴大生物療法的可用性。再加上政府鼓勵醫療基礎建設的政策，進一步推動了市場的成長。此外，亞太地區的研發活動蓬勃發展，國內外製藥公司大力投資生技藥品的開發。蓬勃發展的生物技術生態系統吸引人才並促進創新。該地區各國政府也正在努力簡化核准程序，讓生物製藥公司更容易進入市場。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球生技藥品市場：依產品

  • 基因治療
  • 細胞療法
  • 疫苗
  • 抗體藥物
  • 其他產品

第6章 全球生技藥品市場：依類型

  • 過敏原萃取物
  • 血液製品
  • 人體細胞和組織
  • 蛋白質
  • 異種移植產品
  • 其他類型

第7章 全球生技藥品市場：依用途

  • 自體免疫疾病
  • 感染疾病
  • 癌症
  • 其他用途

第8章 全球生技藥品市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • AbbVie Inc
  • Amgen Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Baxter International Inc
  • Biocon Ltd.
  • Celltrion Healthcare Co. Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc
  • Novartis AG
  • Pfizer Inc
  • Precision Biologics Inc
  • Samsung Electronics Co. Ltd
Product Code: SMRC23948

According to Stratistics MRC, the Global Biologic Therapeutics Market is accounted for $457.56 billion in 2023 and is expected to reach $968.08 billion by 2030 growing at a CAGR of 11.3% during the forecast period. The pharmaceutical industry sector that concentrates on the development, production, and marketing of therapeutic medicines generated from biological sources is referred to as the biologic therapeutics market. These complex chemicals are created using living organisms or their parts, such as proteins, antibodies, nucleic acids, or cells. They are also referred to as biologics or biological pharmaceuticals.

According to World Health Organization, vaccines are one of the most powerful and cost-effective ways to reduce the global burden of disease and are estimated to save 2-3 million lives every year.

Market Dynamics:

Driver:

Increasing prevalence of age-related and chronic diseases and expanding pipeline of biologics

The need for efficient treatment alternatives is being driven by the increased prevalence of chronic diseases like cancer, autoimmune conditions, and metabolic diseases. Biologic medicines provide customized, targeted treatments that can address the underlying causes of many disorders, spurring market expansion. Additionally, the development of biologic medicines has received significant funding from the pharmaceutical and biotechnology industries. Biologic medication development, including recombinant proteins, cell and gene therapies, and monoclonal antibodies, is boosting the market and spurring innovation.

Restraint:

High costs of development and production, manufacturing and supply chain management are quite complex

Complex procedures and high expenditures, such as those associated with research and development, clinical trials, and manufacturing facilities, are involved in the creation and production of biologic therapies. Particularly in healthcare systems with limited resources, these high costs may restrict the availability and affordability of biologic medications. However, due to their complicated nature, biologic pharmaceuticals need specialized production facilities and procedures. It can be difficult to ensure consistent quality, scaleability, and maintain a strong supply chain, which may have an impact on the accessibility and affordability of biologic treatments.

Opportunity:

Biotechnology and genetic engineering advancements and favorable regulatory landscape

The potential for creating innovative biological therapies has increased as a result of ongoing developments in biotechnology, genetic engineering, and recombinant DNA technology. These technological developments make it possible to produce biological medications that are more sophisticated and specifically targeted, expanding the number of available treatments. Additionally, regulatory organizations have established precise rules and accelerated paths for the approval of biologic therapies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). These regulatory regimes offer a favorable environment for the creation, assessment, and marketing of biologic medicines.

Threat:

High standards of regulation and concerns about immunogenicity and safety

Despite the existence of favorable regulatory frameworks, the complex and stringent approval procedures for biologic therapies. Extensive preclinical and clinical trials that must be conducted by companies to prove safety, efficacy, and quality can take a long time and cost a lot of funds. However, patients' immune responses to biological therapies may be induced, raising concerns regarding their safety and immunogenicity. The effectiveness and safety of the treatment may be impacted by these immunological reactions, which can range in severity. For biological treatments to be used effectively, it is crucial to provide effective monitoring and management of these problems.

COVID-19 Impact:

The COVID-19 epidemic made the creation and distribution of efficient vaccinations essential. As a result, vaccine research and development significantly increased, utilizing biological platforms like mRNA and viral vector-based vaccines. The effective creation and application of COVID-19 vaccines highlighted the promise of biological treatments and emphasized the significance of the biotechnology sector in combating infectious diseases.

The blood products segment is expected to be the largest during the forecast period

Blood products segment commanded the largest share over the forecast period. Blood-derived products, including immunoglobulins, clotting factors, and plasma-derived proteins, which are used to treat a variety of blood illnesses and immunological deficiencies, are also considered to be part of biologic therapies. The use of these items is essential in the management of a number of blood diseases, immunological deficiencies, and other ailments.

The cell therapy segment is expected to have the highest CAGR during the forecast period

Cell therapy segment is estimated to witness lucrative growth over the projection period. Living cells are used in cell therapy to treat or cure diseases. It is a fast-developing area that seeks to replace, restore, or fix damaged or sick cells or tissues. Additionally, cell therapy has demonstrated potential in a number of therapeutic fields, including oncology, cardiovascular illness, neurodegenerative disorders, and autoimmune diseases.

Region with largest share:

Asia Pacific is expected to hold largest share over the forecast period as the biological therapies industry experiences substantial development and innovation, the Asia-Pacific region is emerging as a vibrant and quickly changing hub. This region is connected to numerous nations with distinctive healthcare systems, making it a complex yet attractive market. Additionally, the region's growing need for biological treatments is being driven by the prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders.

Region with highest CAGR:

Asia Pacific is estimated to hold highest CAGR. The availability of biological therapies has expanded as a result of an expanding middle-class population and rising healthcare costs. This has further propelled the market's growth, along with government policies to encourage the construction of healthcare infrastructure. Additionally, the Asia-Pacific region is experiencing a boom in research and development activity, with both domestic and foreign pharmaceutical firms making significant investments in the development of biologic drugs. A thriving biotechnology ecosystem has resulted in an outcome that draws in talent and encourages innovation. Governments in the area are also making efforts to simplify approval procedures, improving the simplicity of market access for biopharmaceutical firms.

Key players in the market:

Some of the key players in Biologic Therapeutics Market include: AbbVie Inc, Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Baxter International Inc, Biocon Ltd., Celltrion Healthcare Co. Ltd., GlaxoSmithKline Plc, Merck and Co. Inc, Novartis AG, Pfizer Inc , Precision Biologics Inc and Samsung Electronics Co. Ltd.

Key Developments:

In May 2022, Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, announceD the launch of its new CRYOcheck Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities. The announcement was made at the World Federation of Hemophilia Congress taking place in Montreal

Products Covered:

  • Gene Therapy
  • Cell Therapy
  • Vaccines
  • Antibody Therapeutics
  • Other Products

Types Covered:

  • Allergenic Extracts
  • Blood Products
  • Human Cells and Tissues
  • Protein
  • Xenotransplantation Products
  • Other Types

Applications Covered:

  • Autoimmune Diseases
  • Infectious Diseases
  • Cancer
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biologic Therapeutics Market, By Product

  • 5.1 Introduction
  • 5.2 Gene Therapy
  • 5.3 Cell Therapy
  • 5.4 Vaccines
  • 5.5 Antibody Therapeutics
  • 5.6 Other Products

6 Global Biologic Therapeutics Market, By Type

  • 6.1 Introduction
  • 6.2 Allergenic Extracts
  • 6.3 Blood Products
  • 6.4 Human Cells and Tissues
  • 6.5 Protein
  • 6.6 Xenotransplantation Products
  • 6.7 Other Types

7 Global Biologic Therapeutics Market, By Application

  • 7.1 Introduction
  • 7.2 Autoimmune Diseases
  • 7.3 Infectious Diseases
  • 7.4 Cancer
  • 7.5 Other Applications

8 Global Biologic Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AbbVie Inc
  • 10.2 Amgen Inc.
  • 10.3 AstraZeneca Plc
  • 10.4 Aurobindo Pharma Ltd.
  • 10.5 Baxter International Inc
  • 10.6 Biocon Ltd.
  • 10.7 Celltrion Healthcare Co. Ltd.
  • 10.8 GlaxoSmithKline Plc
  • 10.9 Merck and Co. Inc
  • 10.10 Novartis AG
  • 10.11 Pfizer Inc
  • 10.12 Precision Biologics Inc
  • 10.13 Samsung Electronics Co. Ltd

List of Tables

  • Table 1 Global Biologic Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 4 Global Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 5 Global Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 6 Global Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 7 Global Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 10 Global Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 11 Global Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 12 Global Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 13 Global Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 14 Global Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 15 Global Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 16 Global Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 17 Global Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 18 Global Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 19 Global Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 20 North America Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 22 North America Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 23 North America Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 24 North America Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 25 North America Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 26 North America Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 27 North America Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 28 North America Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 29 North America Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 30 North America Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 31 North America Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 32 North America Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 33 North America Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 34 North America Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 North America Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 36 North America Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 37 North America Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 38 North America Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 39 Europe Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 41 Europe Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 42 Europe Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 43 Europe Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 44 Europe Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 45 Europe Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 46 Europe Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 47 Europe Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 48 Europe Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 49 Europe Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 50 Europe Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 51 Europe Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 52 Europe Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 53 Europe Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 54 Europe Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 55 Europe Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 56 Europe Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 57 Europe Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 58 Asia Pacific Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 60 Asia Pacific Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 61 Asia Pacific Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 62 Asia Pacific Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 63 Asia Pacific Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 64 Asia Pacific Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 65 Asia Pacific Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 67 Asia Pacific Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 68 Asia Pacific Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 69 Asia Pacific Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 70 Asia Pacific Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 71 Asia Pacific Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 72 Asia Pacific Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 73 Asia Pacific Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 74 Asia Pacific Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 75 Asia Pacific Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 76 Asia Pacific Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 77 South America Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 79 South America Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 80 South America Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 81 South America Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 82 South America Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 83 South America Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 84 South America Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 85 South America Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 86 South America Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 87 South America Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 88 South America Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 89 South America Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 90 South America Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 91 South America Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 92 South America Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 93 South America Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 94 South America Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 95 South America Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 96 Middle East & Africa Biologic Therapeutics Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Biologic Therapeutics Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 Middle East & Africa Biologic Therapeutics Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 99 Middle East & Africa Biologic Therapeutics Market Outlook, By Cell Therapy (2021-2030) ($MN)
  • Table 100 Middle East & Africa Biologic Therapeutics Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 101 Middle East & Africa Biologic Therapeutics Market Outlook, By Antibody Therapeutics (2021-2030) ($MN)
  • Table 102 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 103 Middle East & Africa Biologic Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 104 Middle East & Africa Biologic Therapeutics Market Outlook, By Allergenic Extracts (2021-2030) ($MN)
  • Table 105 Middle East & Africa Biologic Therapeutics Market Outlook, By Blood Products (2021-2030) ($MN)
  • Table 106 Middle East & Africa Biologic Therapeutics Market Outlook, By Human Cells and Tissues (2021-2030) ($MN)
  • Table 107 Middle East & Africa Biologic Therapeutics Market Outlook, By Protein (2021-2030) ($MN)
  • Table 108 Middle East & Africa Biologic Therapeutics Market Outlook, By Xenotransplantation Products (2021-2030) ($MN)
  • Table 109 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 110 Middle East & Africa Biologic Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 111 Middle East & Africa Biologic Therapeutics Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 112 Middle East & Africa Biologic Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 113 Middle East & Africa Biologic Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 114 Middle East & Africa Biologic Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)